Multiple sclerosis: New approaches to immunotherapy

Neuroscientist

Volumn 2, Issue 2, 1996, Pages 127-136

  Vollmer, Timothy L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Demyelination; Immunological treatments; Immunology; Multiple sclerosis; Pathogenesis; Therapy

Indexed keywords

EID: 0000108849     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385849600200214     Document Type: Article

References (52)

1. Bever C. The current status of studies of aminopyridines in patients with multiple sclerosis. Ann Neurol 1994;36:S118-S121.
2. Bansil S, Cook SD, Rohowsky-Kochan C. Multiple sclerosis: immune mechanism and update on current therapies. Ann Neurol 1995;37:S87-S101.
3. Vollmer TL, Waxman SG. Demyelinating disorders of the central nervous system. In: Rosenberg RN, editor. Comprehensive neurology. New York: Raven Press 1991;489-523.
4. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
5. Poser CM. The epidemiology of multiple sclerosis: a general overview. Ann Neurol 1994;36(Suppl 2):S180-S193.
6. Booss J, Kim JH. Evidence for a viral etiology of multiple sclerosis. In: Cook SD, editor. Handbook of multiple sclerosis. New York: Marcel Dekker 1990;41-62.
7. Wynn DR, Rodriguez M, O'Fallon WM, Kurland LT. Update on epidemiology of multiple sclerosis. Mayo Clin Proc 1989;64:808-817.
8. Ebers GC. Genetics and multiple sclerosis: an overview. Ann Neurol 1994;36:S12-S14.
9. Cook SD, editor. Handbook of multiple sclerosis. New York: Marcel Dekker 1990.
10. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985;1:1313-1315.
11. Abramsky O. Pregnancy and multiple sclerosis. Ann Neurol 1994; 36:S38-S41.
12. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987;1:893-895.
13. Beck J, Rondot P, Catinot L, et al. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-323.
14. Wekerle H, Kimikazu K, Lannes-Vieira J, Lassmann H, Linington C. Animal models. Ann Neurol 1994;36:S47-S53.
15. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis. Ann Neurol 1995;37:424-435.
16. Brosnan CF, Selmaj K, Raine CS. Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. J Neuroimmunol 1988;18:87-94.
17. Raine C. The immunology of the multiple sclerosis lesion. Ann Neurol 1994;36:S61-S72.
18. Waxman SG. Prerequisites for conduction in demyelinated fibers. Neurology 1978;28(Pt 2):27-34.
19. Sears TA, Bostock H, Sherrart M. The pathophysiology of demyelination and its implications for symptomatic treatment of multiple sclerosis. Neurology 1978;28(Pt 2):21-26.
20. Waxman SG. Demyelination in spinal cord injury and multiple sclerosis: what can we do to enhance functional recovery? J Neurotrauma 1992;9:S105-S117.
21. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44:635-641.
22. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 1983;308:173-180.
23. Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL. Immunosuppression with high-dose IV cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology 1988;38(Suppl 2):9-14.
24. Rosen J. Prolonged azathioprine treatment of non-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1979;42:338-344.
25. Ellison GW, Myers LW, Mickey MR, et al. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology 1989;1018-1026.
26. Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW. The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 1991;41:20-25.
27. Weinblatt ME, Weissman BN, Hodsworth DE, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992;31:129-137.
28. Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37: 30-40.
29. Cook SD, Devereux C, Troiano R, et al. Total lymphoid irradiation in multiple sclerosis: blood lymphocytes and clinical course. Ann Neurol 1987;22:634-638.
30. Cook SD, Bansil S, Boos J, et al. Total Iymphoid irradiation (TLI) and low-dose prednisone (LDP) in progressive multiple sclerosis (PMS). Neurology 1995;45(Suppl 4):A417.
31. Sipe JC, Romine J, Koziol J, Zyroff J, McMillan R, Beutler E. Cladribine treatment of chronic progressive (c/p) MS: a double-blind, crossover study with 2+ years' observation. Neurology 1995;45 (Suppl 4):A418.
32. Troiano R. Corticosteroid therapy in acute multiple sclerosis. In: Cook SD, editor. Handbook of multiple sclerosis. New York: Marcel Dekker 1990;351-370.
33. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in optic neuritis. N Engl J Med 1992;326:581-588.
34. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith BC. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993; 329:1764-1769.
35. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-516.
36. Rudge P. Cyclosporine and multiple sclerosis. In: Cook SD, editor. Handbook of multiple sclerosis. New York: Marcel Dekker 1990;439-454.
37. Weinstock-Guttman B, Ransohoff RM, Kinkel P, Rudick R. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol 1995;37:7-15.
38. IFNB Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993;43:655-661.
39. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB MS Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. Neurology 1993;43:662-667.
40. IFNB MS Study Group, UBC MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
41. Jacobs LL. A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbation-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. In press.
42. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant interferon α-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994;44:406-413.
43. Calabresi PA, Hanham A, Carlino J, Olsen H, et al. Report of an ongoing phase I trial of recombinant transforming growth factor-β 2 (TGF-β2) in chronic progressive multiple sclerosis. Neurology 1995;45 (Suppl 4):A417.
44. Brosnan CF, Cannella B, Battistini L, Raine CS. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology 1995;45:S16-S21.
45. Karussis D, Meiner A, Lehmann D, et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: results of a double-blind placebo-controlled study with monthly MRI evaluation. Neurology 1995;45 (Suppl 4):A417.
46. Hodgkinson SJ, Steinman L. Monoclonal antibodies for treatment of multiple sclerosis. In: Cook SD, editor. Handbook of multiple sclerosis. New York: Marcel Dekker 1990;481-492.
47. Lindsey JW, Hodgkinson S, Mehta R, Mitchel D, Enzmann D, Steinman L. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurology 1994;36:183-189.
48. Webb C, Teitelbaum D, Arnon R, Sela M. In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur J Immunol 1973;3:279-286.
49. Fridkis-Hareli M, Teitelbaum, D, Gurevitch E, et al. Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen presenting cells-specificity and promiscuity. Proc Natl Acad Sci U S A 1994;91:4872-4876.
50. Johnson KP, Brooks BR, Cohen J, et al. Copolymer 1 (Cop 1) reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276.
51. Nelson P, Weiner HL. Oral tolerance in the treatment of autoimmune disease. Practical Allergy & Immunology 1994;9:164-174.
52. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993;259:1321-I324.